AllSquare Wealth Management LLC Sells 900 Shares of Johnson & Johnson (NYSE:JNJ)

AllSquare Wealth Management LLC cut its position in Johnson & Johnson (NYSE:JNJ) by 15.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 4,942 shares of the company’s stock after selling 900 shares during the period. AllSquare Wealth Management LLC’s holdings in Johnson & Johnson were worth $715,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. IFS Advisors LLC boosted its holdings in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $32,000. RPg Family Wealth Advisory LLC purchased a new stake in Johnson & Johnson during the third quarter valued at $35,000. Activest Wealth Management bought a new position in Johnson & Johnson in the third quarter valued at about $40,000. Finally, NewSquare Capital LLC boosted its holdings in shares of Johnson & Johnson by 145.8% in the fourth quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock worth $42,000 after buying an additional 172 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

JNJ stock opened at $162.93 on Friday. The firm has a market cap of $392.63 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The business’s fifty day simple moving average is $156.57 and its two-hundred day simple moving average is $156.34.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the company posted $2.29 earnings per share. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Raymond James cut their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Leerink Partners dropped their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Finally, Morgan Stanley decreased their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.